Ionis Pharmaceuticals (IONS) Net Income towards Common Stockholders (2009 - 2026)

Ionis Pharmaceuticals' Net Income towards Common Stockholders history runs 18 years deep, the most recent figure standing at -$92.5 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 37.03% year-over-year to -$92.5 million in Q1 2026; TTM through Mar 2026 was $26.0 million, a 105.73% increase from a year earlier, with the FY2025 full-year figure at -$391.7 million, up 12.72% from the prior year.
• Net Income towards Common Stockholders eased to -$92.5 million in Q1 2026 per IONS's latest filing, from $123.6 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $325.4 million in Q4 2023 and bottomed at -$147.4 million in Q3 2023.
• The 5-year median for Net Income towards Common Stockholders is -$92.5 million (2026), against an average of -$50.4 million.
• Biggest YoY gain for Net Income towards Common Stockholders was 965.43% in 2023; the steepest drop was 213.69% in 2023.
• Year by year, Net Income towards Common Stockholders stood at -$37.6 million in 2022, then jumped by 965.43% to $325.4 million in 2023, then sank by 130.51% to -$99.3 million in 2024, then surged by 224.45% to $123.6 million in 2025, then sank by 174.89% to -$92.5 million in 2026.
• Per Business Quant, the three latest IONS Net Income towards Common Stockholders figures stand at -$92.5 million (Q1 2026), $123.6 million (Q4 2025), and -$128.6 million (Q3 2025).